Weight-management evidence
Tirzepatide vs Cagrilintide
Tirzepatide has large Phase III/approved-product evidence; cagrilintide monotherapy evidence is Phase II. Compare evidence maturity and mechanism rather than.
At a glance
Tirzepatide
Cagrilintide
Human evidence
Large Phase III obesity evidence shows substantial weight loss. SURMOUNT-OSA additionally demonstrated large reductions in sleep-apnea severity in adults with obesity and moderate-to-severe OSA.
Cagrilintide has randomized Phase II weight-loss evidence and a Phase IIIa monotherapy arm within REDEFINE 1; cagrilintide 2.4 mg weekly produced roughly 11.5%-11.8% mean weight reduction at 68 weeks depending on estimand.
Research focus
Type 2 diabetes, obesity, weight management
Obesity, appetite and weight-management research
Regulatory status
Tirzepatide is authorised in licensed products such as Mounjaro for type 2 diabetes and adult weight management in the EU; authorization is product- and jurisdiction-specific.
FDA states cagrilintide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in U.S. compounding under federal law.
Route / formulation
Unverified research-market material or non-authorised pens are not equivalent to licensed tirzepatide medicines merely because the active-ingredient name matches.
Trial evidence does not establish quality or equivalence of research-market material.
No simple monotherapy head-to-head basis Tirzepatide has large Phase III/approved-product evidence; cagrilintide monotherapy evidence is Phase II. Compare evidence maturity and mechanism rather than declare a winner.